Korea University Anam Hospital

Truqap Offers New Hope for HR+/HER2- Breast Cancer Treatment in Korea

- Truqap (capivasertib), the first AKT inhibitor, is now available in Korea for HR+/HER2- locally advanced or metastatic breast cancer patients with PIK3CA, AKT1, and PTEN mutations. - Clinical trials demonstrated Truqap's efficacy in improving median progression-free survival (mPFS) by 7.3 months compared to fulvestrant monotherapy's 3.1 months in patients who failed first-line endocrine therapy. - Truqap has shown a 30% improvement in overall survival (OS) in clinical trials, offering a significant advantage for second-line treatment options. - Truqap's clinical trial enrolled a patient population more reflective of real-world scenarios, including those previously treated with CDK4/6 inhibitors, making the data more relevant for clinical application.